Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celator receives orphan drug designation for leukemia drug
Celator is currently preparing to conduct two randomized Phase II studies with CPX-351. The first Phase II study, in newly diagnosed, elderly patients with acute myeloid leukemia (AML)
Celator is currently preparing to conduct two randomized Phase II studies with CPX-351. The first Phase II study, in newly diagnosed, elderly patients with acute myeloid leukemia (AML)
The glioblastoma multiforme (GBM) clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite
Jeffrey Burbank, president and CEO of NxStage Medical, said: “We are very pleased to affirm our long-standing relationship as DaVita’s preferred bloodline vendor. “This contract demonstrates both the
The announcement came on the heels of FDA’s clearance for the Pathwork Tissue of Origin test for diagnosis of tumors of uncertain origin, including poorly differentiated, undifferentiated and
Bilcare Global Clinical Supplies’s (GCS) latest Phase III investments include the upgrade of its Kalish large-scale bottling line at its US facility and an investment in new Pentapack
Amrubicin is a third-generation, synthetic anthracycline analogue that has demonstrated substantial clinical efficacy in the treatment of small cell lung cancer. Amrubicin has been granted orphan-drug designation for
Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of
Dirucotide (MBP8298) is currently being evaluated in a US pivotal Phase III trial, named Maestro-03, at 68 sites with approximately 510 patients. Kevin Giese, president and CEO of
Most recently, Dr Hensby served as the vice president of R&D and regulatory affairs for Ivrea Pharmaceuticals. Dr Hensby is a graduate BSc in pharmacology from Kings College,
The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination versus bortezomib alone. The